No party, no drugs? Use of stimulants, dissociative drugs, and GHB/GBL during the early COVID-19 pandemic.
Amphetamine
Cocaine
Corona
Ketamine
MDMA
Substance use
Journal
The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
07
07
2021
revised:
15
12
2021
accepted:
29
12
2021
pubmed:
31
1
2022
medline:
1
4
2022
entrez:
30
1
2022
Statut:
ppublish
Résumé
The COVID-19 pandemic is presumably having an impact on the consumption of psychoactive substances. Social distancing and lockdown measures may particularly affect the use of "party drugs" (e.g., stimulants, dissociatives, and GHB/GBL) through the absence of typical use settings. We aimed to analyse the use patterns of those substances and underlying motivations before and during the pandemic. A subsample of 1,231 users of stimulants (amphetamine, methamphetamine, MDMA/ecstasy, cocaine), dissociative drugs (ketamine, dextromethorphan, PCP), and GHB/GBL was assessed from 30th April to 4th August 2020 as part of the Corona Drug Survey, a cross-sectional international online survey in five languages that included a total of 5,049 participants. The reported use of distinct substances and the underlying motivations were ascertained before (retrospectively) and during the pandemic. Furthermore, associations between drug use as a coping mechanism, pandemic-related stressors, and substance use were examined. Regarding the reported frequency of use during the pandemic, 48.0-64.8% of the sample ceased or decreased, 11.9-25.5% maintained, and 23.6-29.1% increased their consumption. MDMA/ecstasy showed the strongest decrease and GHB/GBL and dissociatives the highest increase. Participants reported that price, quality, and supply were mostly unaffected by the pandemic. The most common motivations before and during the pandemic were mood-related factors, such as a desire to feel exhilarated, euphoric, high, or buzzed. The relevance of social purposes and mood-related motivators declined during the pandemic, whereas dealing with boredom increased. Overall, 16.4-35.6% perceived drug use as helpful for dealing with pandemic-related stressors, which were associated with an increased consumption frequency. The early stage of the COVID-19 pandemic was associated with major changes in the use of "party drugs". Those who increased their level of drug use and perceived it as a coping strategy in particular might be targeted with adaptive preventive and therapeutic measures.
Sections du résumé
BACKGROUND
The COVID-19 pandemic is presumably having an impact on the consumption of psychoactive substances. Social distancing and lockdown measures may particularly affect the use of "party drugs" (e.g., stimulants, dissociatives, and GHB/GBL) through the absence of typical use settings. We aimed to analyse the use patterns of those substances and underlying motivations before and during the pandemic.
METHODS
A subsample of 1,231 users of stimulants (amphetamine, methamphetamine, MDMA/ecstasy, cocaine), dissociative drugs (ketamine, dextromethorphan, PCP), and GHB/GBL was assessed from 30th April to 4th August 2020 as part of the Corona Drug Survey, a cross-sectional international online survey in five languages that included a total of 5,049 participants. The reported use of distinct substances and the underlying motivations were ascertained before (retrospectively) and during the pandemic. Furthermore, associations between drug use as a coping mechanism, pandemic-related stressors, and substance use were examined.
RESULTS
Regarding the reported frequency of use during the pandemic, 48.0-64.8% of the sample ceased or decreased, 11.9-25.5% maintained, and 23.6-29.1% increased their consumption. MDMA/ecstasy showed the strongest decrease and GHB/GBL and dissociatives the highest increase. Participants reported that price, quality, and supply were mostly unaffected by the pandemic. The most common motivations before and during the pandemic were mood-related factors, such as a desire to feel exhilarated, euphoric, high, or buzzed. The relevance of social purposes and mood-related motivators declined during the pandemic, whereas dealing with boredom increased. Overall, 16.4-35.6% perceived drug use as helpful for dealing with pandemic-related stressors, which were associated with an increased consumption frequency.
CONCLUSION
The early stage of the COVID-19 pandemic was associated with major changes in the use of "party drugs". Those who increased their level of drug use and perceived it as a coping strategy in particular might be targeted with adaptive preventive and therapeutic measures.
Identifiants
pubmed: 35093679
pii: S0955-3959(22)00004-4
doi: 10.1016/j.drugpo.2022.103582
pmc: PMC8730379
pii:
doi:
Substances chimiques
Sodium Oxybate
7G33012534
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103582Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declarations of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
BMC Public Health. 2020 May 27;20(1):790
pubmed: 32460799
Int J Drug Policy. 2020 Sep;83:102834
pubmed: 32646713
Int J Drug Policy. 2021 Apr;90:103097
pubmed: 33485187
Int J Drug Policy. 2017 Dec;50:1-8
pubmed: 28869878
Int J Drug Policy. 2020 Sep;83:102829
pubmed: 32595070
J Youth Adolesc. 2018 Aug;47(8):1755-1770
pubmed: 29774451
Subst Abus. 2020;41(4):409-412
pubmed: 33044893
J Anxiety Disord. 2021 Apr;79:102377
pubmed: 33662702
JMIR Public Health Surveill. 2020 Sep 18;6(3):e19630
pubmed: 32589149
Soc Sci Med. 2017 Oct;190:29-37
pubmed: 28837863
Eur Addict Res. 2021;27(1):25-32
pubmed: 32535605
Fortschr Neurol Psychiatr. 2016 Nov;84(11):690-698
pubmed: 27846654
J Adolesc Health. 2020 Sep;67(3):354-361
pubmed: 32693983
J Addict Dis. 2020 Oct-Dec;38(4):580-581
pubmed: 32752939
Nutrients. 2020 Jun 03;12(6):
pubmed: 32503173
Drug Alcohol Rev. 2020 May;39(4):297-300
pubmed: 32445265
Health Educ Res. 2001 Aug;16(4):457-69
pubmed: 11525392
Int J Drug Policy. 2020 Sep;83:102895
pubmed: 32741718
Brain Behav. 2020 Sep;10(9):e01745
pubmed: 32633464
Sci Total Environ. 2021 Feb 25;757:144006
pubmed: 33310574
JAMA. 2020 Oct 27;324(16):1674-1677
pubmed: 32945855
Subst Abus. 2020;41(3):286-291
pubmed: 32697172
Int J Drug Policy. 2021 Jun;92:103127
pubmed: 33549464
Subst Use Misuse. 2021;56(2):238-244
pubmed: 33317365
Int J Environ Res Public Health. 2020 Jun 29;17(13):
pubmed: 32610613
Psychiatr Prax. 2019 Nov;46(8):445-450
pubmed: 31683335
Drug Alcohol Rev. 2020 May;39(4):301-304
pubmed: 32358884
Int J Drug Policy. 2019 Nov;73:81-87
pubmed: 31349134
Eur Addict Res. 2019;25(6):283-292
pubmed: 31302656
Eur Addict Res. 2020;26(6):309-315
pubmed: 32961535
CNS Drugs. 2017 Jan;31(1):51-64
pubmed: 28004314
Psychiatry Res. 2020 Jul;289:113096
pubmed: 32405115
Int J Drug Policy. 2021 Jul;93:102904
pubmed: 32861536
Brain Behav. 2021 Feb;11(2):e01964
pubmed: 33230969
Am J Addict. 2020 Jul;29(4):268-270
pubmed: 32500608
Am J Ind Med. 2016 Sep;59(9):742-51
pubmed: 27582476
BMC Psychiatry. 2013 Mar 28;13:104
pubmed: 23537095